NCT02293850 is a Phase 1 clinical trial of OBP-301 in Carcinoma, Hepatocellular, sponsored by Oncolys BioPharma Inc.

Who is sponsoring NCT02293850?

NCT02293850 is sponsored by Oncolys BioPharma Inc.

What drugs are being tested in NCT02293850?

Interventions in NCT02293850: OBP-301.

What condition does NCT02293850 study?

NCT02293850 studies Carcinoma, Hepatocellular.

Is NCT02293850 still recruiting?

NCT02293850 is currently status unknown. Last updated 16 August 2018.

Last reviewed 2018-08-16 · How we verify

NCT02293850

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Status unknown Phase 1 Last updated 16 August 2018

What this trial tests

Phase 1 trial testing OBP-301 in Carcinoma, Hepatocellular in 18 participants. Status unknown.

Timeline

1 October 2014

Primary endpoint
1 April 2019

1 April 2021

Quick facts

Lead sponsor	Oncolys BioPharma Inc
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	1 October 2014
Primary completion	1 April 2019
Estimated completion	1 April 2021
Sites	2 locations across South Korea, Taiwan

Drugs / interventions tested

OBP-301 — full drug profile →

Conditions studied

Carcinoma, Hepatocellular — all drugs for Carcinoma, Hepatocellular →

Sponsor

Oncolys BioPharma Inc

Who can join

Adults 18 to 65, any sex, with Carcinoma, Hepatocellular. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Evaluation of safety parameters (adverse events, laboratory data, EKG, body weight, vital signs) on patient-base.
Time frame: 14 weeks

Sponsor's own description

This is an open labeled, multiple centers, two countries (Taiwan and Korea) non-comparative phase I trial in patients with hepatocellular carcinoma. In phase I part, a maximum of 18 patients will be recruited in this study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization.
Maier P, Hartmann L, Wenz F, Herskind C. · · 2016 · cited 282× · PMID 26784176 · DOI 10.3390/ijms17010102
Recent advances of oncolytic virus in cancer therapy.
Mondal M, Guo J, He P, Zhou D. · · 2020 · cited 154× · PMID 32078405 · DOI 10.1080/21645515.2020.1723363
Hepatocellular carcinoma: signaling pathways and therapeutic advances.
Zheng J, Wang S, Xia L, Sun Z, et al · · 2025 · cited 142× · PMID 39915447 · DOI 10.1038/s41392-024-02075-w
Trial Watch-Oncolytic viruses and cancer therapy.
Pol J, Buqué A, Aranda F, Bloy N, et al · · 2016 · cited 87× · PMID 27057469 · DOI 10.1080/2162402x.2015.1117740
Telomere and Telomerase Therapeutics in Cancer.
Xu Y, Goldkorn A. · · 2016 · cited 84× · PMID 27240403 · DOI 10.3390/genes7060022
Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies.
Liu X, Yin L, Shen S, Hou Y. · · 2023 · cited 75× · PMID 37013041 · DOI 10.1016/j.gendis.2021.09.006
Concepts in Oncolytic Adenovirus Therapy.
Mantwill K, Klein FG, Wang D, Hindupur SV, et al · · 2021 · cited 75× · PMID 34638863 · DOI 10.3390/ijms221910522
Designer Oncolytic Adenovirus: Coming of Age.
Baker AT, Aguirre-Hernández C, Halldén G, Parker AL. · · 2018 · cited 66× · PMID 29904022 · DOI 10.3390/cancers10060201

Verify or expand the search:

Other trials of OBP-301

Trials testing the same drug.

NCT04685499 — Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperabl · Phase 2 · terminated
NCT03172819 — Special Combination of OBP-301 and Pembrolizumab · Phase 1 · completed
NCT03190824 — Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma · Phase 2 · unknown

Other recruiting trials for Carcinoma, Hepatocellular

Currently open trials in the same condition.

NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT06742892 — A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to · Phase 2 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06349980 — A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02293850 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oncolys BioPharma Inc
Last refreshed: 16 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02293850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing